Zymeworks, Inc.

How big is Zymeworks, Inc.?

As of Jun 18, Zymeworks, Inc. has a market capitalization of 859.90 million and reported net sales of 93.38 million, with a net profit loss of 113.69 million over the latest four quarters.

As of Jun 18, Zymeworks, Inc. has a market capitalization of 859.90 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 93.38 million for the latest four quarters. However, it also experienced a net profit loss of 113.69 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 338.77 million and total assets amounting to 463.09 million.

What does Zymeworks, Inc. do?

Zymeworks, Inc. is a clinical-stage biopharmaceutical company focused on developing bio-therapeutics for cancer treatment, with a market cap of approximately $859.90 million. As of March 2025, it reported net sales of $27 million and a net loss of $23 million.

Overview: <BR>Zymeworks, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 27 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 859.90 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: -29.66% <BR>Price to Book: 2.65<BR><BR>Contact Details: <BR>Address: 540-1385 West 8Th Avenue, VANCOUVER BC: V6H 3V9 <BR>Tel: 1 604 6781388 <BR>Website: https://www.zymeworks.com/

Should I buy, sell or hold Zymeworks, Inc.?

Is Zymeworks, Inc. overvalued or undervalued?

As of March 6, 2024, Zymeworks, Inc. is considered overvalued with a risky valuation grade, reflected by a price-to-book ratio of 2.72, an EV to EBITDA of -6.53, a ROCE of -171.02%, and a year-to-date return of -14.82%, contrasting sharply with its peers and the S&P 500's performance.

As of 6 March 2024, Zymeworks, Inc. has moved from an attractive to a risky valuation grade, indicating a shift in investor sentiment towards the company. The current analysis suggests that Zymeworks is overvalued given its financial metrics. The price-to-book value stands at 2.72, while the EV to EBITDA ratio is -6.53, and the ROCE is a concerning -171.02%. <BR><BR>In comparison to its peers, Zymeworks' valuation ratios are significantly weaker; for instance, Harrow, Inc. has an EV to EBITDA of 60.41, while Evolus, Inc. shows an EV to EBITDA of -21.94, both indicating more favorable valuations in their respective contexts. Additionally, Zymeworks' recent stock performance has been underwhelming, with a year-to-date return of -14.82%, contrasting with a 2.44% gain in the S&P 500, further reinforcing the notion of overvaluation in light of its current financial struggles.

Is Zymeworks, Inc. technically bullish or bearish?

As of August 25, 2025, Zymeworks, Inc. has a bullish technical trend supported by strong indicators, outperforming the S&P 500 with a 17.37% return over the past month and 31.71% over the past year.

As of 25 August 2025, the technical trend for Zymeworks, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate bullish momentum. Daily moving averages are bullish, and the On-Balance Volume (OBV) is bullish as well. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames.<BR><BR>In terms of performance, Zymeworks has outperformed the S&P 500 over the past month with a return of 17.37% compared to the S&P 500's 2.33%, and it has also shown strong returns over the past year at 31.71% versus 17.14% for the benchmark.